Healthcare / Drug Manufacturers - Specialty & GenericKSE
$18860.00
-100.00 (-0.53%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $17.5B · quality 36.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
52/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$209.7B
P/E
4.8x
↓EV/EBITDA
5.3x
↓ROE
8.9%
↑Gross Margin
17.9%
↓Debt/Equity
0.89
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.4%
FCF CAGR
—
FCF margin
4.1%
FCF / Net income
0.68x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $722.31B · net income $43.49B · FCF $29.61B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $722.31B | $722.31B | $653.26B | $594.57B | $634.97B |
| Net Income | $43.49B | $43.49B | $18.28B | $6.12B | $33.98B |
| EBITDA | $111.97B | $111.97B | $92.09B | $70.15B | $98.70B |
| EPS | 3911.00 | 3911.00 | 1644.00 | 550.00 | 3056.00 |
| Gross Margin | 17.9% | 17.9% | 15.8% | 17.1% | 21.6% |
| Operating Margin | 7.0% | 7.0% | 5.2% | 7.2% | 9.8% |
| Net Margin | 6.0% | 6.0% | 2.8% | 1.0% | 5.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.89 | 0.89 | 0.99 | 1.10 | 0.96 |
| Current Ratio | 1.22 | 1.22 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $29.61B | $29.61B | $17.46B | $-41.77B | $-11.27B |
| Returns | |||||
| ROE | 8.9% | 8.9% | 4.0% | 1.4% | 8.1% |
| Valuation | |||||
| P/E | 4.82 | 4.82 | 8.02 | 50.91 | 10.57 |
| EV/EBITDA | 5.33 | 5.33 | 6.06 | 10.56 | 7.36 |
| P/B | 0.43 | 0.43 | 0.32 | 0.73 | 0.85 |
| Growth & Yield | |||||
| Revenue Growth | 10.6% | 10.6% | 9.9% | -6.4% | — |
| EPS Growth | 137.9% | 137.9% | 198.9% | -82.0% | — |
| Dividend Yield | 2.6% | 2.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-24.6%
EPS terminal req.
$1673.51
Spread vs growth
162.5%
5Y implied EPS CAGR
-12.3%
EPS terminal req.
$2024.95
Spread vs growth
150.2%
10Y implied EPS CAGR
-1.8%
EPS terminal req.
$3261.20
Spread vs growth
139.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+4.6%
Start / end P/E
11.3x → 4.8x
EPS bridge
1644.00 → 3911.00
Residual
-78.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.